A Multicenter, Randomized, Placebo-Controlled, Crossover Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 Compared to Placebo in the Treatment of Cancer Breakthrough Pain

Trial Profile

A Multicenter, Randomized, Placebo-Controlled, Crossover Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 Compared to Placebo in the Treatment of Cancer Breakthrough Pain

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2015

At a glance

  • Drugs Sufentanil (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 May 2010 Primary endpoint 'Sum of pain intensity difference' has been met, according to an AcelRx Pharmaceuticals media release.
    • 25 May 2010 Results have been reported in a AcelRx Pharmaceuticals media release.
    • 07 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top